Talphera, Inc. (TLPH)
NASDAQ: TLPH · Real-Time Price · USD
0.7223
-0.0554 (-7.12%)
At close: Apr 2, 2026, 4:00 PM EDT
0.779599
+0.0573 (7.93%)
After-hours: Apr 2, 2026, 7:27 PM EDT
Talphera Revenue
In the year 2025, Talphera had annual revenue of $28.00K.
Revenue (ttm)
$28.00K
Revenue Growth
n/a
P/S Ratio
1,291.11
Revenue / Employee
$2,333
Employees
12
Market Cap
36.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 28.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 651.00K | -2.69M | -80.51% |
| Dec 31, 2022 | 3.34M | 523.00K | 18.56% |
| Dec 31, 2021 | 2.82M | -2.60M | -47.97% |
| Dec 31, 2020 | 5.42M | 3.13M | 136.61% |
| Dec 31, 2019 | 2.29M | 138.00K | 6.42% |
| Dec 31, 2018 | 2.15M | -5.84M | -73.10% |
| Dec 31, 2017 | 8.00M | -9.36M | -53.94% |
| Dec 31, 2016 | 17.36M | -1.91M | -9.89% |
| Dec 31, 2015 | 19.26M | 14.05M | 269.24% |
| Dec 31, 2014 | 5.22M | -24.29M | -82.32% |
| Dec 31, 2013 | 29.50M | 27.11M | 1,132.33% |
| Dec 31, 2012 | 2.39M | 1.32M | 123.32% |
| Dec 31, 2011 | 1.07M | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| InterCure | 72.16M |
| Rockwell Medical | 69.26M |
| Aytu BioPharma | 62.64M |
| Cumberland Pharmaceuticals | 44.52M |
| BGM Group | 25.10M |
| Zhengye Biotechnology Holding | 21.46M |
| SCYNEXIS | 20.60M |
| TherapeuticsMD | 3.02M |
TLPH News
- 10 days ago - Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026 - PRNewsWire
- 12 days ago - Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 17 days ago - Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026 - PRNewsWire
- 4 weeks ago - Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial - PRNewsWire
- 5 months ago - Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 5 months ago - Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025 - PRNewsWire
- 5 months ago - Talphera Announces the Appointment of Joe Todisco to Board of Directors - PRNewsWire
- 7 months ago - CorMedix Announces Strategic Minority Investment in Talphera - GlobeNewsWire